Abstract
The unprecedented challenge posed by the COVID-19 pandemic, driven by SARS-CoV-2, has emerged as a global threat. In response, a limited array of therapeutics has been approved for the prevention and treatment of SARS-CoV-2 infection. The main protease (Mpro) of SARS-CoV-2 has been a significant target for drug development efforts because of its crucial role in the viral replication process. This study is to investigate the efficacy of Ensitrelvir and its derivatives in inhibiting the mechanism of the Mpro target of SAR-CoV-2. Docking simulation and molecular dynamic simulation (SMD) techniques were employed for this purpose. The results indicate that the CID 166498740 derivative obtained affinity energy -9.3 kcal/mol and rupture force (Fmax) 638.3 ± 79.3 (pN), which proved that the CID 166498740 derivative strongly interacted with the Mpro target, emphasizing non-binding interactions as more crucial than hydrogen bonding in stabilizing the receptor-ligand conformation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
